ClearPoint Neuro, Inc. Announces Retirement of Director John N. Spencer, Jr.
13 avr. 2021 16h05 HE
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro, Inc. Congratulates uniQure on Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
06 avr. 2021 16h05 HE
|
ClearPoint Neuro, Inc.
IRVINE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain,...
ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel
24 mars 2021 16h05 HE
|
ClearPoint Neuro, Inc.
IRVINE, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain,...
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2020 Results
04 mars 2021 16h05 HE
|
ClearPoint Neuro, Inc.
Company Reports Record Revenues IRVINE, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing...
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2020 Results on March 4, 2021
19 févr. 2021 16h05 HE
|
ClearPoint Neuro, Inc.
IRVINE, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain,...
ClearPoint Neuro, Inc. Announces License and Research Agreement with Philips
18 févr. 2021 16h05 HE
|
ClearPoint Neuro, Inc.
Collaboration will Enable ClearPoint to Develop and Launch the ClearPoint ‘Maestro™’ Brain Model by 2022 IRVINE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT)...
ClearPoint Neuro, Inc. Announces Multi-Product Joint Development & Option Agreement with Blackrock Microsystems
11 févr. 2021 16h05 HE
|
ClearPoint Neuro, Inc.
IRVINE, Calif. and SALT LAKE CITY, Utah, Feb. 11, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and...
ClearPoint Neuro, Inc. Announces Expansion of Pre-Clinical and Translational Development Team to Support Gene and Stem Cell Therapy Partners
26 janv. 2021 16h05 HE
|
ClearPoint Neuro, Inc.
IRVINE, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced...
ClearPoint Neuro, Inc. Announces First Procedure Utilizing ClearPoint® 2.0 Software in Europe
14 janv. 2021 16h05 HE
|
ClearPoint Neuro, Inc.
IRVINE, Calif., Jan. 14, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today reported the...
ClearPoint Neuro, Inc. Announces Funding of Additional $7.5M of Existing Convertible Note on Improved Terms
29 déc. 2020 16h15 HE
|
ClearPoint Neuro, Inc.
IRVINE, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain,...